Quartet of biotechs join Nasdaq after stellar IPOs
Braveheart Bio, Latigo Biotherapeutics, Attovia Therapeutics, and BlossomHill Therapeutics have finalised their Nasdaq listings, collectively raising more than $1.2 billion – with all overshooting their predicted proceeds. Braveheart heads the trio in …